#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Epilepsy is a disorder in the central nervous system ( CNS ) that is characterized by an increase in the number of electrical impulses that occurs in one focal locus of the brain and/or the entire brain , resulting in partial or generalized seizures .
2-1	16-24	Epilepsy	abstract	new	coref	2-3[3_0]
2-2	25-27	is	_	_	_	_
2-3	28-29	a	abstract[3]	giv[3]	coref	6-3[0_3]
2-4	30-38	disorder	abstract[3]	giv[3]	_	_
2-5	39-41	in	abstract[3]	giv[3]	_	_
2-6	42-45	the	abstract[3]|abstract[4]	giv[3]|new[4]	appos	2-11[0_4]
2-7	46-53	central	abstract[3]|abstract[4]	giv[3]|new[4]	_	_
2-8	54-61	nervous	abstract[3]|abstract[4]	giv[3]|new[4]	_	_
2-9	62-68	system	abstract[3]|abstract[4]	giv[3]|new[4]	_	_
2-10	69-70	(	_	_	_	_
2-11	71-74	CNS	abstract	giv	_	_
2-12	75-76	)	_	_	_	_
2-13	77-81	that	_	_	_	_
2-14	82-84	is	_	_	_	_
2-15	85-98	characterized	_	_	_	_
2-16	99-101	by	_	_	_	_
2-17	102-104	an	event[6]	new[6]	_	_
2-18	105-113	increase	event[6]	new[6]	_	_
2-19	114-116	in	event[6]	new[6]	_	_
2-20	117-120	the	event[6]|abstract[7]	new[6]|new[7]	_	_
2-21	121-127	number	event[6]|abstract[7]	new[6]|new[7]	_	_
2-22	128-130	of	event[6]|abstract[7]	new[6]|new[7]	_	_
2-23	131-141	electrical	event[6]|abstract[7]|abstract[8]	new[6]|new[7]|new[8]	_	_
2-24	142-150	impulses	event[6]|abstract[7]|abstract[8]	new[6]|new[7]|new[8]	_	_
2-25	151-155	that	event[6]|abstract[7]|abstract[8]	new[6]|new[7]|new[8]	_	_
2-26	156-162	occurs	event[6]|abstract[7]|abstract[8]	new[6]|new[7]|new[8]	_	_
2-27	163-165	in	event[6]|abstract[7]|abstract[8]	new[6]|new[7]|new[8]	_	_
2-28	166-169	one	event[6]|abstract[7]|abstract[8]|abstract[9]	new[6]|new[7]|new[8]|new[9]	_	_
2-29	170-175	focal	event[6]|abstract[7]|abstract[8]|abstract[9]	new[6]|new[7]|new[8]|new[9]	_	_
2-30	176-181	locus	event[6]|abstract[7]|abstract[8]|abstract[9]	new[6]|new[7]|new[8]|new[9]	_	_
2-31	182-184	of	event[6]|abstract[7]|abstract[8]|abstract[9]	new[6]|new[7]|new[8]|new[9]	_	_
2-32	185-188	the	event[6]|abstract[7]|abstract[8]|abstract[9]|object[10]	new[6]|new[7]|new[8]|new[9]|new[10]	_	_
2-33	189-194	brain	event[6]|abstract[7]|abstract[8]|abstract[9]|object[10]	new[6]|new[7]|new[8]|new[9]|new[10]	_	_
2-34	195-201	and/or	event[6]|abstract[7]|abstract[8]|abstract[9]	new[6]|new[7]|new[8]|new[9]	_	_
2-35	202-205	the	event[6]|abstract[7]|abstract[8]|abstract[9]|object[11]	new[6]|new[7]|new[8]|new[9]|new[11]	coref	5-12[0_11]
2-36	206-212	entire	event[6]|abstract[7]|abstract[8]|abstract[9]|object[11]	new[6]|new[7]|new[8]|new[9]|new[11]	_	_
2-37	213-218	brain	event[6]|abstract[7]|abstract[8]|abstract[9]|object[11]	new[6]|new[7]|new[8]|new[9]|new[11]	_	_
2-38	219-220	,	_	_	_	_
2-39	221-230	resulting	_	_	_	_
2-40	231-233	in	_	_	_	_
2-41	234-241	partial	event[12]	new[12]	coref	5-5[24_12]
2-42	242-244	or	event[12]	new[12]	_	_
2-43	245-256	generalized	event[12]	new[12]	_	_
2-44	257-265	seizures	event[12]	new[12]	_	_
2-45	266-267	.	_	_	_	_

#Text=The administration of antiepileptic drugs is mostly done via the oral or intravenous routes .
3-1	268-271	The	event[13]	new[13]	coref	11-21[0_13]
3-2	272-286	administration	event[13]	new[13]	_	_
3-3	287-289	of	event[13]	new[13]	_	_
3-4	290-303	antiepileptic	event[13]|substance[14]	new[13]|new[14]	coref	7-1[39_14]
3-5	304-309	drugs	event[13]|substance[14]	new[13]|new[14]	_	_
3-6	310-312	is	_	_	_	_
3-7	313-319	mostly	_	_	_	_
3-8	320-324	done	_	_	_	_
3-9	325-328	via	_	_	_	_
3-10	329-332	the	place[15]	new[15]	_	_
3-11	333-337	oral	place[15]	new[15]	_	_
3-12	338-340	or	place[15]	new[15]	_	_
3-13	341-352	intravenous	place[15]	new[15]	_	_
3-14	353-359	routes	place[15]	new[15]	_	_
3-15	360-361	.	_	_	_	_

#Text=Drug resistance at the late stage of therapy develops in about 40 % of patients .
4-1	362-366	Drug	substance|abstract[17]	new|new[17]	coref|coref	5-1|5-1[23_17]
4-2	367-377	resistance	abstract[17]	new[17]	_	_
4-3	378-380	at	abstract[17]	new[17]	_	_
4-4	381-384	the	abstract[17]|time[18]	new[17]|new[18]	_	_
4-5	385-389	late	abstract[17]|time[18]	new[17]|new[18]	_	_
4-6	390-395	stage	abstract[17]|time[18]	new[17]|new[18]	_	_
4-7	396-398	of	abstract[17]|time[18]	new[17]|new[18]	_	_
4-8	399-406	therapy	abstract[17]|time[18]|event	new[17]|new[18]|new	_	_
4-9	407-415	develops	_	_	_	_
4-10	416-418	in	_	_	_	_
4-11	419-424	about	abstract[20]	new[20]	_	_
4-12	425-427	40	abstract[20]	new[20]	_	_
4-13	428-429	%	abstract[20]	new[20]	_	_
4-14	430-432	of	abstract[20]	new[20]	_	_
4-15	433-441	patients	abstract[20]|person	new[20]|new	coref	6-1[30_0]
4-16	442-443	.	_	_	_	_

#Text=Drug resistance leads to uncontrolled seizures , a higher risk of brain damage , and increased mortality rates .
5-1	444-448	Drug	substance|abstract[23]	giv|giv[23]	coref|coref	7-22|7-22[46_23]
5-2	449-459	resistance	abstract[23]	giv[23]	_	_
5-3	460-465	leads	_	_	_	_
5-4	466-468	to	_	_	_	_
5-5	469-481	uncontrolled	event[24]|event[25]	giv[24]|giv[25]	coref|coref	5-5[25_24]|6-11[0_25]
5-6	482-490	seizures	event[24]|event[25]	giv[24]|giv[25]	_	_
5-7	491-492	,	event[25]	giv[25]	_	_
5-8	493-494	a	event[25]|abstract[26]	giv[25]|new[26]	_	_
5-9	495-501	higher	event[25]|abstract[26]	giv[25]|new[26]	_	_
5-10	502-506	risk	event[25]|abstract[26]	giv[25]|new[26]	_	_
5-11	507-509	of	event[25]|abstract[26]	giv[25]|new[26]	_	_
5-12	510-515	brain	event[25]|abstract[26]|object|event[28]	giv[25]|new[26]|giv|new[28]	coref	8-19
5-13	516-522	damage	event[25]|abstract[26]|event[28]	giv[25]|new[26]|new[28]	_	_
5-14	523-524	,	event[25]	giv[25]	_	_
5-15	525-528	and	event[25]	giv[25]	_	_
5-16	529-538	increased	event[25]|abstract[29]	giv[25]|new[29]	_	_
5-17	539-548	mortality	event[25]|abstract[29]	giv[25]|new[29]	_	_
5-18	549-554	rates	event[25]|abstract[29]	giv[25]|new[29]	_	_
5-19	555-556	.	_	_	_	_

#Text=Patients with epilepsy suffer from emotional and behavioral changes , seizures , convulsions , muscular spasms , depression and , in some cases , unconsciousness .
6-1	557-565	Patients	person[30]	giv[30]	_	_
6-2	566-570	with	person[30]	giv[30]	_	_
6-3	571-579	epilepsy	person[30]|abstract	giv[30]|giv	coref	7-7
6-4	580-586	suffer	_	_	_	_
6-5	587-591	from	_	_	_	_
6-6	592-601	emotional	event[32]	new[32]	_	_
6-7	602-605	and	event[32]	new[32]	_	_
6-8	606-616	behavioral	event[32]	new[32]	_	_
6-9	617-624	changes	event[32]	new[32]	_	_
6-10	625-626	,	_	_	_	_
6-11	627-635	seizures	event	giv	_	_
6-12	636-637	,	_	_	_	_
6-13	638-649	convulsions	event	new	_	_
6-14	650-651	,	_	_	_	_
6-15	652-660	muscular	event[35]	new[35]	_	_
6-16	661-667	spasms	event[35]	new[35]	_	_
6-17	668-669	,	_	_	_	_
6-18	670-680	depression	abstract	new	_	_
6-19	681-684	and	_	_	_	_
6-20	685-686	,	_	_	_	_
6-21	687-689	in	_	_	_	_
6-22	690-694	some	abstract[37]|abstract[38]	new[37]|new[38]	_	_
6-23	695-700	cases	abstract[37]|abstract[38]	new[37]|new[38]	_	_
6-24	701-702	,	abstract[38]	new[38]	_	_
6-25	703-718	unconsciousness	abstract[38]	new[38]	_	_
6-26	719-720	.	_	_	_	_

#Text=Drugs used for the treatment of epilepsy have poor bioavailability and eventually become ineffective over the course of treatment due to drug resistance .
7-1	721-726	Drugs	substance[39]	giv[39]	coref	9-6[60_39]
7-2	727-731	used	substance[39]	giv[39]	_	_
7-3	732-735	for	substance[39]	giv[39]	_	_
7-4	736-739	the	substance[39]|event[40]	giv[39]|new[40]	coref	7-19[0_40]
7-5	740-749	treatment	substance[39]|event[40]	giv[39]|new[40]	_	_
7-6	750-752	of	substance[39]|event[40]	giv[39]|new[40]	_	_
7-7	753-761	epilepsy	substance[39]|event[40]|abstract	giv[39]|new[40]|giv	coref	8-1
7-8	762-766	have	_	_	_	_
7-9	767-771	poor	abstract[42]	new[42]	coref	11-1[76_42]
7-10	772-787	bioavailability	abstract[42]	new[42]	_	_
7-11	788-791	and	_	_	_	_
7-12	792-802	eventually	_	_	_	_
7-13	803-809	become	_	_	_	_
7-14	810-821	ineffective	_	_	_	_
7-15	822-826	over	_	_	_	_
7-16	827-830	the	time[43]	new[43]	_	_
7-17	831-837	course	time[43]	new[43]	_	_
7-18	838-840	of	time[43]	new[43]	_	_
7-19	841-850	treatment	time[43]|event	new[43]|giv	coref	8-1[48_0]
7-20	851-854	due	_	_	_	_
7-21	855-857	to	_	_	_	_
7-22	858-862	drug	substance|abstract[46]	giv|giv[46]	coref	8-12[50_0]
7-23	863-873	resistance	abstract[46]	giv[46]	_	_
7-24	874-875	.	_	_	_	_

#Text=Epilepsy treatment is often complicated due to the poor release of the drug through the adjunctive blood – brain barrier , which may be overcome by the preparation of the drug as solid lipid nanoparticles .
8-1	876-884	Epilepsy	abstract|event[48]	giv|giv[48]	coref	17-16
8-2	885-894	treatment	event[48]	giv[48]	_	_
8-3	895-897	is	_	_	_	_
8-4	898-903	often	_	_	_	_
8-5	904-915	complicated	_	_	_	_
8-6	916-919	due	_	_	_	_
8-7	920-922	to	_	_	_	_
8-8	923-926	the	event[49]	new[49]	coref	9-13[63_49]
8-9	927-931	poor	event[49]	new[49]	_	_
8-10	932-939	release	event[49]	new[49]	_	_
8-11	940-942	of	event[49]	new[49]	_	_
8-12	943-946	the	event[49]|substance[50]	new[49]|giv[50]	coref	8-30[55_50]
8-13	947-951	drug	event[49]|substance[50]	new[49]|giv[50]	_	_
8-14	952-959	through	event[49]	new[49]	_	_
8-15	960-963	the	event[49]|object[53]	new[49]|new[53]	_	_
8-16	964-974	adjunctive	event[49]|object[53]	new[49]|new[53]	_	_
8-17	975-980	blood	event[49]|substance|object[53]	new[49]|new|new[53]	_	_
8-18	981-982	–	event[49]|object[53]	new[49]|new[53]	_	_
8-19	983-988	brain	event[49]|object|object[53]	new[49]|giv|new[53]	coref	9-22[65_0]
8-20	989-996	barrier	event[49]|object[53]	new[49]|new[53]	_	_
8-21	997-998	,	event[49]	new[49]	_	_
8-22	999-1004	which	event[49]	new[49]	_	_
8-23	1005-1008	may	event[49]	new[49]	_	_
8-24	1009-1011	be	event[49]	new[49]	_	_
8-25	1012-1020	overcome	event[49]	new[49]	_	_
8-26	1021-1023	by	event[49]	new[49]	_	_
8-27	1024-1027	the	event[49]|event[54]	new[49]|new[54]	_	_
8-28	1028-1039	preparation	event[49]|event[54]	new[49]|new[54]	_	_
8-29	1040-1042	of	event[49]|event[54]	new[49]|new[54]	_	_
8-30	1043-1046	the	event[49]|event[54]|substance[55]	new[49]|new[54]|giv[55]	coref	9-16[0_55]
8-31	1047-1051	drug	event[49]|event[54]|substance[55]	new[49]|new[54]|giv[55]	_	_
8-32	1052-1054	as	event[49]	new[49]	_	_
8-33	1055-1060	solid	event[49]|object[57]	new[49]|new[57]	coref	13-1[91_57]
8-34	1061-1066	lipid	event[49]|substance|object[57]	new[49]|new|new[57]	coref	13-2
8-35	1067-1080	nanoparticles	event[49]|object[57]	new[49]|new[57]	_	_
8-36	1081-1082	.	_	_	_	_

#Text=The ideal delivery systems of antiepileptic drugs are the ones which provide localized and controlled drug release to targeted sites in the brain , which helps to reduce drug-associated toxicities and enhances the efficacy of the drug .
9-1	1083-1086	The	object[59]	new[59]	coref	9-9[61_59]
9-2	1087-1092	ideal	object[59]	new[59]	_	_
9-3	1093-1101	delivery	abstract|object[59]	new|new[59]	coref	19-17[140_0]
9-4	1102-1109	systems	object[59]	new[59]	_	_
9-5	1110-1112	of	object[59]	new[59]	_	_
9-6	1113-1126	antiepileptic	object[59]|substance[60]	new[59]|giv[60]	coref	16-18[119_60]
9-7	1127-1132	drugs	object[59]|substance[60]	new[59]|giv[60]	_	_
9-8	1133-1136	are	_	_	_	_
9-9	1137-1140	the	object[61]	giv[61]	coref	13-12[94_61]
9-10	1141-1145	ones	object[61]	giv[61]	_	_
9-11	1146-1151	which	object[61]	giv[61]	_	_
9-12	1152-1159	provide	object[61]	giv[61]	_	_
9-13	1160-1169	localized	object[61]|event[63]	giv[61]|giv[63]	_	_
9-14	1170-1173	and	object[61]|event[63]	giv[61]|giv[63]	_	_
9-15	1174-1184	controlled	object[61]|event[63]	giv[61]|giv[63]	_	_
9-16	1185-1189	drug	object[61]|substance|event[63]	giv[61]|giv|giv[63]	coref	9-36[68_0]
9-17	1190-1197	release	object[61]|event[63]	giv[61]|giv[63]	_	_
9-18	1198-1200	to	object[61]|event[63]	giv[61]|giv[63]	_	_
9-19	1201-1209	targeted	object[61]|event[63]|place[64]	giv[61]|giv[63]|new[64]	_	_
9-20	1210-1215	sites	object[61]|event[63]|place[64]	giv[61]|giv[63]|new[64]	_	_
9-21	1216-1218	in	object[61]|event[63]|place[64]	giv[61]|giv[63]|new[64]	_	_
9-22	1219-1222	the	object[61]|event[63]|place[64]|object[65]	giv[61]|giv[63]|new[64]|giv[65]	coref	12-11[0_65]
9-23	1223-1228	brain	object[61]|event[63]|place[64]|object[65]	giv[61]|giv[63]|new[64]|giv[65]	_	_
9-24	1229-1230	,	object[61]|event[63]	giv[61]|giv[63]	_	_
9-25	1231-1236	which	object[61]|event[63]	giv[61]|giv[63]	_	_
9-26	1237-1242	helps	object[61]|event[63]	giv[61]|giv[63]	_	_
9-27	1243-1245	to	object[61]|event[63]	giv[61]|giv[63]	_	_
9-28	1246-1252	reduce	object[61]|event[63]	giv[61]|giv[63]	_	_
9-29	1253-1268	drug-associated	object[61]|event[63]|abstract[66]	giv[61]|giv[63]|new[66]	_	_
9-30	1269-1279	toxicities	object[61]|event[63]|abstract[66]	giv[61]|giv[63]|new[66]	_	_
9-31	1280-1283	and	object[61]|event[63]	giv[61]|giv[63]	_	_
9-32	1284-1292	enhances	object[61]|event[63]	giv[61]|giv[63]	_	_
9-33	1293-1296	the	object[61]|event[63]|abstract[67]	giv[61]|giv[63]|new[67]	coref	17-10[125_67]
9-34	1297-1305	efficacy	object[61]|event[63]|abstract[67]	giv[61]|giv[63]|new[67]	_	_
9-35	1306-1308	of	object[61]|event[63]|abstract[67]	giv[61]|giv[63]|new[67]	_	_
9-36	1309-1312	the	object[61]|event[63]|abstract[67]|substance[68]	giv[61]|giv[63]|new[67]|giv[68]	_	_
9-37	1313-1317	drug	object[61]|event[63]|abstract[67]|substance[68]	giv[61]|giv[63]|new[67]|giv[68]	_	_
9-38	1318-1319	.	_	_	_	_

#Text=Carbamazepine ( CBZ ) is an antiepileptic drug with a narrow therapeutic index , and it is poorly absorbed when taken by the oral route .
10-1	1320-1333	Carbamazepine	substance	new	coref	10-6[71_0]
10-2	1334-1335	(	_	_	_	_
10-3	1336-1339	CBZ	abstract	new	coref	21-23[158_0]
10-4	1340-1341	)	_	_	_	_
10-5	1342-1344	is	_	_	_	_
10-6	1345-1347	an	substance[71]	giv[71]	ana	11-1[0_71]
10-7	1348-1361	antiepileptic	substance[71]	giv[71]	_	_
10-8	1362-1366	drug	substance[71]	giv[71]	_	_
10-9	1367-1371	with	substance[71]	giv[71]	_	_
10-10	1372-1373	a	substance[71]|abstract[72]	giv[71]|new[72]	ana	10-16[0_72]
10-11	1374-1380	narrow	substance[71]|abstract[72]	giv[71]|new[72]	_	_
10-12	1381-1392	therapeutic	substance[71]|abstract[72]	giv[71]|new[72]	_	_
10-13	1393-1398	index	substance[71]|abstract[72]	giv[71]|new[72]	_	_
10-14	1399-1400	,	_	_	_	_
10-15	1401-1404	and	_	_	_	_
10-16	1405-1407	it	abstract	giv	_	_
10-17	1408-1410	is	_	_	_	_
10-18	1411-1417	poorly	_	_	_	_
10-19	1418-1426	absorbed	_	_	_	_
10-20	1427-1431	when	_	_	_	_
10-21	1432-1437	taken	_	_	_	_
10-22	1438-1440	by	_	_	_	_
10-23	1441-1444	the	abstract[74]	new[74]	_	_
10-24	1445-1449	oral	abstract[74]	new[74]	_	_
10-25	1450-1455	route	abstract[74]	new[74]	_	_
10-26	1456-1457	.	_	_	_	_

#Text=Its oral bioavailability is 75 % , and its maximum achieved plasma concentration is about 4 – 8 h after administration .
11-1	1458-1461	Its	substance|abstract[76]	giv|giv[76]	coref|ana	11-5[77_76]|11-9
11-2	1462-1466	oral	abstract[76]	giv[76]	_	_
11-3	1467-1482	bioavailability	abstract[76]	giv[76]	_	_
11-4	1483-1485	is	_	_	_	_
11-5	1486-1488	75	abstract[77]|abstract[78]	giv[77]|giv[78]	coref|coref	11-5[78_77]|16-14[118_78]
11-6	1489-1490	%	abstract[77]|abstract[78]	giv[77]|giv[78]	_	_
11-7	1491-1492	,	abstract[78]	giv[78]	_	_
11-8	1493-1496	and	abstract[78]	giv[78]	_	_
11-9	1497-1500	its	abstract[78]|substance|abstract[81]	giv[78]|giv|new[81]	coref|coref	11-15[82_81]|12-1
11-10	1501-1508	maximum	abstract[78]|abstract[81]	giv[78]|new[81]	_	_
11-11	1509-1517	achieved	abstract[78]|abstract[81]	giv[78]|new[81]	_	_
11-12	1518-1524	plasma	abstract[78]|substance|abstract[81]	giv[78]|new|new[81]	_	_
11-13	1525-1538	concentration	abstract[78]|abstract[81]	giv[78]|new[81]	_	_
11-14	1539-1541	is	abstract[78]	giv[78]	_	_
11-15	1542-1547	about	abstract[78]|abstract[82]	giv[78]|giv[82]	_	_
11-16	1548-1549	4	abstract[78]|abstract[82]	giv[78]|giv[82]	_	_
11-17	1550-1551	–	abstract[78]|abstract[82]	giv[78]|giv[82]	_	_
11-18	1552-1553	8	abstract[78]|abstract[82]	giv[78]|giv[82]	_	_
11-19	1554-1555	h	abstract[78]|abstract[82]	giv[78]|giv[82]	_	_
11-20	1556-1561	after	abstract[78]|abstract[82]	giv[78]|giv[82]	_	_
11-21	1562-1576	administration	abstract[78]|abstract[82]|event	giv[78]|giv[82]|giv	_	_
11-22	1577-1578	.	_	_	_	_

#Text=Carbamazepine acts through the inactivation of sodium channels , making brain cells less excitable .
12-1	1579-1592	Carbamazepine	substance	giv	coref	15-19
12-2	1593-1597	acts	_	_	_	_
12-3	1598-1605	through	_	_	_	_
12-4	1606-1609	the	event[85]	new[85]	_	_
12-5	1610-1622	inactivation	event[85]	new[85]	_	_
12-6	1623-1625	of	event[85]	new[85]	_	_
12-7	1626-1632	sodium	event[85]|substance|object[87]	new[85]|new|new[87]	_	_
12-8	1633-1641	channels	event[85]|object[87]	new[85]|new[87]	_	_
12-9	1642-1643	,	_	_	_	_
12-10	1644-1650	making	_	_	_	_
12-11	1651-1656	brain	object|animal[89]	giv|new[89]	_	_
12-12	1657-1662	cells	animal[89]	new[89]	_	_
12-13	1663-1667	less	_	_	_	_
12-14	1668-1677	excitable	_	_	_	_
12-15	1678-1679	.	_	_	_	_

#Text=Solid lipid nanoparticles ( SLNs ) are considered an alternative to colloidal systems like liposome , noisome and polymeric nanoparticles .
13-1	1680-1685	Solid	object[91]	giv[91]	coref	13-19[97_91]
13-2	1686-1691	lipid	substance|object[91]	giv|giv[91]	coref	17-7
13-3	1692-1705	nanoparticles	object[91]	giv[91]	_	_
13-4	1706-1707	(	_	_	_	_
13-5	1708-1712	SLNs	abstract	new	coref	14-1
13-6	1713-1714	)	_	_	_	_
13-7	1715-1718	are	_	_	_	_
13-8	1719-1729	considered	_	_	_	_
13-9	1730-1732	an	abstract[93]	new[93]	_	_
13-10	1733-1744	alternative	abstract[93]	new[93]	_	_
13-11	1745-1747	to	abstract[93]	new[93]	_	_
13-12	1748-1757	colloidal	abstract[93]|object[94]	new[93]|giv[94]	_	_
13-13	1758-1765	systems	abstract[93]|object[94]	new[93]|giv[94]	_	_
13-14	1766-1770	like	abstract[93]|object[94]	new[93]|giv[94]	_	_
13-15	1771-1779	liposome	abstract[93]|object[94]|substance	new[93]|giv[94]|new	_	_
13-16	1780-1781	,	abstract[93]|object[94]	new[93]|giv[94]	_	_
13-17	1782-1789	noisome	abstract[93]|object[94]|abstract	new[93]|giv[94]|new	_	_
13-18	1790-1793	and	abstract[93]|object[94]	new[93]|giv[94]	_	_
13-19	1794-1803	polymeric	abstract[93]|object[94]|object[97]	new[93]|giv[94]|giv[97]	coref	17-5[124_97]
13-20	1804-1817	nanoparticles	abstract[93]|object[94]|object[97]	new[93]|giv[94]|giv[97]	_	_
13-21	1818-1819	.	_	_	_	_

#Text=SLNs consist of solid lipids , which act as a stabilizer when dispersed in water in the presence of a surfactant .
14-1	1820-1824	SLNs	abstract	giv	_	_
14-2	1825-1832	consist	_	_	_	_
14-3	1833-1835	of	_	_	_	_
14-4	1836-1841	solid	substance[99]	new[99]	_	_
14-5	1842-1848	lipids	substance[99]	new[99]	_	_
14-6	1849-1850	,	substance[99]	new[99]	_	_
14-7	1851-1856	which	substance[99]	new[99]	_	_
14-8	1857-1860	act	substance[99]	new[99]	_	_
14-9	1861-1863	as	substance[99]	new[99]	_	_
14-10	1864-1865	a	substance[99]|object[100]	new[99]|new[100]	_	_
14-11	1866-1876	stabilizer	substance[99]|object[100]	new[99]|new[100]	_	_
14-12	1877-1881	when	_	_	_	_
14-13	1882-1891	dispersed	_	_	_	_
14-14	1892-1894	in	_	_	_	_
14-15	1895-1900	water	substance	new	_	_
14-16	1901-1903	in	_	_	_	_
14-17	1904-1907	the	abstract[102]	new[102]	_	_
14-18	1908-1916	presence	abstract[102]	new[102]	_	_
14-19	1917-1919	of	abstract[102]	new[102]	_	_
14-20	1920-1921	a	abstract[102]|substance[103]	new[102]|new[103]	_	_
14-21	1922-1932	surfactant	abstract[102]|substance[103]	new[102]|new[103]	_	_
14-22	1933-1934	.	_	_	_	_

#Text=SLN is characterized by its small size ( nano range ) , large surface area , and high drug loading capacity .
15-1	1935-1938	SLN	abstract	new	ana	15-5
15-2	1939-1941	is	_	_	_	_
15-3	1942-1955	characterized	_	_	_	_
15-4	1956-1958	by	_	_	_	_
15-5	1959-1962	its	abstract|abstract[106]	giv|new[106]	appos	15-9[108_106]
15-6	1963-1968	small	abstract[106]	new[106]	_	_
15-7	1969-1973	size	abstract[106]	new[106]	_	_
15-8	1974-1975	(	_	_	_	_
15-9	1976-1980	nano	object|abstract[108]	new|giv[108]	coref	21-13[156_108]
15-10	1981-1986	range	abstract[108]	giv[108]	_	_
15-11	1987-1988	)	_	_	_	_
15-12	1989-1990	,	_	_	_	_
15-13	1991-1996	large	abstract[110]	new[110]	_	_
15-14	1997-2004	surface	place|abstract[110]	new|new[110]	_	_
15-15	2005-2009	area	abstract[110]	new[110]	_	_
15-16	2010-2011	,	_	_	_	_
15-17	2012-2015	and	_	_	_	_
15-18	2016-2020	high	abstract[113]	new[113]	ana	16-4[0_113]
15-19	2021-2025	drug	substance|abstract[112]|abstract[113]	giv|new[112]|new[113]	coref	16-6
15-20	2026-2033	loading	abstract[112]|abstract[113]	new[112]|new[113]	_	_
15-21	2034-2042	capacity	abstract[113]	new[113]	_	_
15-22	2043-2044	.	_	_	_	_

#Text=In addition , it improves drug stability and has the ability to improve the oral bioavailability of poorly water-soluble drugs .
16-1	2045-2047	In	_	_	_	_
16-2	2048-2056	addition	_	_	_	_
16-3	2057-2058	,	_	_	_	_
16-4	2059-2061	it	abstract	giv	coref	16-10[117_0]
16-5	2062-2070	improves	_	_	_	_
16-6	2071-2075	drug	substance|abstract[116]	giv|new[116]	coref	18-5
16-7	2076-2085	stability	abstract[116]	new[116]	_	_
16-8	2086-2089	and	_	_	_	_
16-9	2090-2093	has	_	_	_	_
16-10	2094-2097	the	abstract[117]	giv[117]	_	_
16-11	2098-2105	ability	abstract[117]	giv[117]	_	_
16-12	2106-2108	to	abstract[117]	giv[117]	_	_
16-13	2109-2116	improve	abstract[117]	giv[117]	_	_
16-14	2117-2120	the	abstract[117]|abstract[118]	giv[117]|giv[118]	coref	21-8[154_118]
16-15	2121-2125	oral	abstract[117]|abstract[118]	giv[117]|giv[118]	_	_
16-16	2126-2141	bioavailability	abstract[117]|abstract[118]	giv[117]|giv[118]	_	_
16-17	2142-2144	of	abstract[117]|abstract[118]	giv[117]|giv[118]	_	_
16-18	2145-2151	poorly	abstract[117]|abstract[118]|substance[119]	giv[117]|giv[118]|giv[119]	_	_
16-19	2152-2165	water-soluble	abstract[117]|abstract[118]|substance[119]	giv[117]|giv[118]|giv[119]	_	_
16-20	2166-2171	drugs	abstract[117]|abstract[118]|substance[119]	giv[117]|giv[118]|giv[119]	_	_
16-21	2172-2173	.	_	_	_	_

#Text=Gangurde and Kumar prepared lamotrigine solid lipid nanoparticles with a high efficacy for treatment of epilepsy .
17-1	2174-2182	Gangurde	person	new	_	_
17-2	2183-2186	and	_	_	_	_
17-3	2187-2192	Kumar	person	new	coref	19-1
17-4	2193-2201	prepared	_	_	_	_
17-5	2202-2213	lamotrigine	object|object[124]	new|giv[124]	coref	18-5[131_124]
17-6	2214-2219	solid	object[124]	giv[124]	_	_
17-7	2220-2225	lipid	substance|object[124]	giv|giv[124]	coref	18-7
17-8	2226-2239	nanoparticles	object[124]	giv[124]	_	_
17-9	2240-2244	with	_	_	_	_
17-10	2245-2246	a	abstract[125]	giv[125]	_	_
17-11	2247-2251	high	abstract[125]	giv[125]	_	_
17-12	2252-2260	efficacy	abstract[125]	giv[125]	_	_
17-13	2261-2264	for	abstract[125]	giv[125]	_	_
17-14	2265-2274	treatment	abstract[125]|abstract[126]	giv[125]|new[126]	_	_
17-15	2275-2277	of	abstract[125]|abstract[126]	giv[125]|new[126]	_	_
17-16	2278-2286	epilepsy	abstract[125]|abstract[126]|abstract	giv[125]|new[126]|giv	ana	18-11
17-17	2287-2288	.	_	_	_	_

#Text=Nair et al. prepared carbamazepine solid lipid nanoparticles to improve its therapeutic effect .
18-1	2289-2293	Nair	person	new	_	_
18-2	2294-2296	et	_	_	_	_
18-3	2297-2300	al.	_	_	_	_
18-4	2301-2309	prepared	_	_	_	_
18-5	2310-2323	carbamazepine	substance|object[131]	giv|giv[131]	coref|coref	19-5[136_131]|20-10
18-6	2324-2329	solid	object[131]	giv[131]	_	_
18-7	2330-2335	lipid	substance|object[131]	giv|giv[131]	coref	19-6
18-8	2336-2349	nanoparticles	object[131]	giv[131]	_	_
18-9	2350-2352	to	_	_	_	_
18-10	2353-2360	improve	_	_	_	_
18-11	2361-2364	its	abstract|abstract[133]	giv|new[133]	_	_
18-12	2365-2376	therapeutic	abstract[133]	new[133]	_	_
18-13	2377-2383	effect	abstract[133]	new[133]	_	_
18-14	2384-2385	.	_	_	_	_

#Text=Kumar et al. prepared solid lipid nanoparticles of methylthioadenosine for the management of neurological conditions via oral delivery .
19-1	2386-2391	Kumar	person	giv	_	_
19-2	2392-2394	et	_	_	_	_
19-3	2395-2398	al.	_	_	_	_
19-4	2399-2407	prepared	_	_	_	_
19-5	2408-2413	solid	object[136]	giv[136]	coref	20-10[145_136]
19-6	2414-2419	lipid	substance|object[136]	giv|giv[136]	coref	20-12
19-7	2420-2433	nanoparticles	object[136]	giv[136]	_	_
19-8	2434-2436	of	object[136]	giv[136]	_	_
19-9	2437-2456	methylthioadenosine	object[136]|abstract	giv[136]|new	_	_
19-10	2457-2460	for	_	_	_	_
19-11	2461-2464	the	organization[138]	new[138]	_	_
19-12	2465-2475	management	organization[138]	new[138]	_	_
19-13	2476-2478	of	organization[138]	new[138]	_	_
19-14	2479-2491	neurological	organization[138]|abstract[139]	new[138]|new[139]	_	_
19-15	2492-2502	conditions	organization[138]|abstract[139]	new[138]|new[139]	_	_
19-16	2503-2506	via	organization[138]	new[138]	_	_
19-17	2507-2511	oral	organization[138]|abstract[140]	new[138]|giv[140]	_	_
19-18	2512-2520	delivery	organization[138]|abstract[140]	new[138]|giv[140]	_	_
19-19	2521-2522	.	_	_	_	_

#Text=The objective of the current study was to prepare carbamazepine solid lipid nanoparticles ( CBZ-SLNs ) as a novel and alternative method for other colloidal dispersion carriers .
20-1	2523-2526	The	abstract[141]	new[141]	_	_
20-2	2527-2536	objective	abstract[141]	new[141]	_	_
20-3	2537-2539	of	abstract[141]	new[141]	_	_
20-4	2540-2543	the	abstract[141]|abstract[142]	new[141]|new[142]	coref	21-1[150_142]
20-5	2544-2551	current	abstract[141]|abstract[142]	new[141]|new[142]	_	_
20-6	2552-2557	study	abstract[141]|abstract[142]	new[141]|new[142]	_	_
20-7	2558-2561	was	_	_	_	_
20-8	2562-2564	to	_	_	_	_
20-9	2565-2572	prepare	_	_	_	_
20-10	2573-2586	carbamazepine	substance|object[145]	giv|giv[145]	_	_
20-11	2587-2592	solid	object[145]	giv[145]	_	_
20-12	2593-2598	lipid	substance|object[145]	giv|giv[145]	_	_
20-13	2599-2612	nanoparticles	object[145]	giv[145]	_	_
20-14	2613-2614	(	_	_	_	_
20-15	2615-2623	CBZ-SLNs	abstract	new	coref	21-6
20-16	2624-2625	)	_	_	_	_
20-17	2626-2628	as	_	_	_	_
20-18	2629-2630	a	abstract[147]	new[147]	_	_
20-19	2631-2636	novel	abstract[147]	new[147]	_	_
20-20	2637-2640	and	abstract[147]	new[147]	_	_
20-21	2641-2652	alternative	abstract[147]	new[147]	_	_
20-22	2653-2659	method	abstract[147]	new[147]	_	_
20-23	2660-2663	for	abstract[147]	new[147]	_	_
20-24	2664-2669	other	abstract[147]|abstract[149]	new[147]|new[149]	_	_
20-25	2670-2679	colloidal	abstract[147]|abstract[149]	new[147]|new[149]	_	_
20-26	2680-2690	dispersion	abstract[147]|abstract|abstract[149]	new[147]|new|new[149]	_	_
20-27	2691-2699	carriers	abstract[147]|abstract[149]	new[147]|new[149]	_	_
20-28	2700-2701	.	_	_	_	_

#Text=The study aimed to prepare CBZ-SLNs with high entrapment efficiency % , small particle size , and high anticonvulsant activity compared to free CBZ .
21-1	2702-2705	The	abstract[150]	giv[150]	_	_
21-2	2706-2711	study	abstract[150]	giv[150]	_	_
21-3	2712-2717	aimed	_	_	_	_
21-4	2718-2720	to	_	_	_	_
21-5	2721-2728	prepare	_	_	_	_
21-6	2729-2737	CBZ-SLNs	abstract	giv	_	_
21-7	2738-2742	with	_	_	_	_
21-8	2743-2747	high	abstract[154]	giv[154]	_	_
21-9	2748-2758	entrapment	abstract|abstract[153]|abstract[154]	new|new[153]|giv[154]	_	_
21-10	2759-2769	efficiency	abstract[153]|abstract[154]	new[153]|giv[154]	_	_
21-11	2770-2771	%	abstract[154]	giv[154]	_	_
21-12	2772-2773	,	_	_	_	_
21-13	2774-2779	small	abstract[156]	giv[156]	_	_
21-14	2780-2788	particle	object|abstract[156]	new|giv[156]	_	_
21-15	2789-2793	size	abstract[156]	giv[156]	_	_
21-16	2794-2795	,	_	_	_	_
21-17	2796-2799	and	_	_	_	_
21-18	2800-2804	high	abstract[157]	new[157]	_	_
21-19	2805-2819	anticonvulsant	abstract[157]	new[157]	_	_
21-20	2820-2828	activity	abstract[157]	new[157]	_	_
21-21	2829-2837	compared	abstract[157]	new[157]	_	_
21-22	2838-2840	to	abstract[157]	new[157]	_	_
21-23	2841-2845	free	abstract[157]|abstract[158]	new[157]|giv[158]	_	_
21-24	2846-2849	CBZ	abstract[157]|abstract[158]	new[157]|giv[158]	_	_
21-25	2850-2851	.	_	_	_	_
